BiotechDueDiligence and HSP90 Central will be covering the 2013 AACR Annual Meeting live from Washington DC. This post will focus on abstracts to be presented by Array Biopharma ARRY and Astex Pharmaceuticals ASTX.
Full coverage:
Introduction
Preview Part 1
Preview Part 2
Full coverage:
Introduction
Preview Part 1
Preview Part 2
(Abstract Numbers link to fulltext c/o AACR)
Array Biopharma ARRY presentations at AACR 2013:
The design and early development of the p38/Tie-2 inhibitor: Array-614 in hematologic cancers - Kevin Koch (link)
Part of an educational session so likely more of a review vs. new data.
MEK162, an allosteric MEK inhibitor promotes apoptosis and in vivo antitumor activity against human biliary cancer cell lines - J. Yang et al (Abstract 934)
A B-RAF-MEK complex reveals a kinase-independent role for BRAF in MAPK pathway suppression - M. Shiva et al (Abstract 2346)
Array Biopharma ARRY presentations at AACR 2013:
The design and early development of the p38/Tie-2 inhibitor: Array-614 in hematologic cancers - Kevin Koch (link)
Part of an educational session so likely more of a review vs. new data.
MEK162, an allosteric MEK inhibitor promotes apoptosis and in vivo antitumor activity against human biliary cancer cell lines - J. Yang et al (Abstract 934)
A B-RAF-MEK complex reveals a kinase-independent role for BRAF in MAPK pathway suppression - M. Shiva et al (Abstract 2346)
Astex Pharmaceuticals ASTX presentations at AACR 2013:
Next-generation hypomethylator SGI-110 (click for intro)
Evaluation of oral bioavailability and intermittent dosing schedules for pharmacodynamic effects by SGI-110, a novel subcutaneous (SQ) second generation hypomethylating agent (HMA), in male cynomolgus monkeys - Oganesian et al (Abstract 678) Sunday 4/7
Non-human primate studies directly related to the ongoing phase 1/2 trial of SGI-110 in MDS/AML patients which was evaluating different dosing schedules for the next-generation DACOGEN (decitabine) drug.
The novel, small molecule DNA methylation inhibitor SGI-110 as an ovarian cancer chemosensitizer - Tang et al (Abstract 4623)
Ovarian cancer is the solid tumor indication that ASTX has indicated that they will start a trial in in 2013. The two abstracts below may offer hints at other tumor possibilities, but the company has not specified.
SGI-110 and entinostat therapy reduces lung tumor burden and reprograms the epigenome - Tellex et al (Abstract 679)
In vivo immunomodulatory activity of SGI-110, a second generation hypomethylating agent, in hematologic malignancies - Covre et al (Abstract 680)
Other pipeline programs:
Novel aurora plus Bruton's tyrosine kinase-targeted therapies for aggressive B-cell non-Hodgkin's lymphoma - Mahadevan et al (Abstract 3388)
AT-IAP, a dual cIAP1 and XIAP antagonist with oral antitumor activity in melanoma models - Chessari et al (Abstract 2944)
A phase 2 study of Amuvatinib (MP-470), the first RAD51 inhibitor in combination with platinum-etoposide (PE) in refractory or relapsed small cell lung cancer (ESCAPE) - Byers et al (Abstract 2095)
The full data presentation for this SCLC trial - BDD readers were well ahead of the curve in expecting the abandonment of this drug candidate.
Presentations related Astex's HSP90 inhibitor AT13387 were covered in an earlier post.
Next-generation hypomethylator SGI-110 (click for intro)
Evaluation of oral bioavailability and intermittent dosing schedules for pharmacodynamic effects by SGI-110, a novel subcutaneous (SQ) second generation hypomethylating agent (HMA), in male cynomolgus monkeys - Oganesian et al (Abstract 678) Sunday 4/7
Non-human primate studies directly related to the ongoing phase 1/2 trial of SGI-110 in MDS/AML patients which was evaluating different dosing schedules for the next-generation DACOGEN (decitabine) drug.
The novel, small molecule DNA methylation inhibitor SGI-110 as an ovarian cancer chemosensitizer - Tang et al (Abstract 4623)
Ovarian cancer is the solid tumor indication that ASTX has indicated that they will start a trial in in 2013. The two abstracts below may offer hints at other tumor possibilities, but the company has not specified.
SGI-110 and entinostat therapy reduces lung tumor burden and reprograms the epigenome - Tellex et al (Abstract 679)
In vivo immunomodulatory activity of SGI-110, a second generation hypomethylating agent, in hematologic malignancies - Covre et al (Abstract 680)
Other pipeline programs:
Novel aurora plus Bruton's tyrosine kinase-targeted therapies for aggressive B-cell non-Hodgkin's lymphoma - Mahadevan et al (Abstract 3388)
AT-IAP, a dual cIAP1 and XIAP antagonist with oral antitumor activity in melanoma models - Chessari et al (Abstract 2944)
A phase 2 study of Amuvatinib (MP-470), the first RAD51 inhibitor in combination with platinum-etoposide (PE) in refractory or relapsed small cell lung cancer (ESCAPE) - Byers et al (Abstract 2095)
The full data presentation for this SCLC trial - BDD readers were well ahead of the curve in expecting the abandonment of this drug candidate.
Presentations related Astex's HSP90 inhibitor AT13387 were covered in an earlier post.
RSS Feed
